Skip to main content

Table 3 Multivariate Cox regression analysis of factors associated with OS in NSCLC

From: miR-4317 suppresses non-small cell lung cancer (NSCLC) by targeting fibroblast growth factor 9 (FGF9) and cyclin D2 (CCND2)

Factor

Training group (n = 162)

Test group (n = 140)

95% CI

RR

p

95% CI

RR

p

Sex (male vs. female)

0.43–1.41

0.78

0.40

0.75–3.41

1.60

0.22

Age (≤ 60 y vs. >  60 y)

0.73–2.06

1.23

0.44

0.83–2.80

1.52

0.18

Tumor size (≤ 5 cm vs. >  5 cm)

0.75–2.39

1.34

0.33

0.40–1.61

0.81

0.54

Tumor stages (T1 + T2 vs. T3 + T4)

0.40–1.53

0.79

0.48

0.71–3.54

1.58

0.26

Histological type (adenocarcinoma vs. squamous cell carcinoma)

0.31–1.07

0.57

0.08

0.40–1.80

0.85

0.68

Histologic grade (well/moderate vs. poor/NS)

0.61–1.90

1.08

0.80

0.62–2.11

1.14

0.68

Lymph node metastasis (negative vs. positive)

0.77–3.32

1.63

0.18

0.96–4.21

2.01

0.06

Clinical stages (I + II vs. III + IV)

0.73–4.50

3.73

0.23

0.63–3.46

1.48

0.37

miR-4317 expression level (low vs. high)

0.14–0.58

0.29

0.001

0.09–0.63

0.24

0.004